Literature DB >> 11221886

P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line.

F Vikhanskaya1, S Marchini, M Marabese, E Galliera, M Broggini.   

Abstract

We examined the consequences of p73alpha overexpression on gene expression and cellular response to anticancer agents in clones from the human ovarian cancer cell line A2780. Using microarray filters, the expression of 588 genes in two clones overexpressing p73alpha (A2780/p73.4 and A2780/ p73.5) in comparison with empty vector-transfected cells was evaluated. There were clear differences in gene expression profiles. Both of the clones showed a marked increase in the expression of genes involved in DNA repair, including genes participating in nucleotide excision repair and mismatch repair. This was confirmed by reverse transcription-PCR and Northern blot analysis and was associated with an increase in the ability of p73alpha-expressing clones to repair two different DDP (cis-dichlorodiammine platinum)-damaged plasmids in a host reactivation assay. p73alpha overexpressing clones were less sensitive than parental cells to alkylating agents treatment or UV radiation but equally sensitive to the topoisomerase I inhibitor topotecan, which indicated that the increase in expression of DNA repair genes has implications for the response to DNA damaging agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221886

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice.

Authors:  Alice Nemajerova; Oleksi Petrenko; Lorenz Trümper; Gustavo Palacios; Ute M Moll
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

2.  TAp73alpha protects small cell lung carcinoma cells from caspase-2 induced mitochondrial mediated apoptotic cell death.

Authors:  Naveen Muppani; Ulrika Nyman; Bertrand Joseph
Journal:  Oncotarget       Date:  2011-12

3.  Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression.

Authors:  Hidetaka Uramoto; Hiroto Izumi; Gunji Nagatani; Haruki Ohmori; Naofumi Nagasue; Tomoko Ise; Takeshi Yoshida; Kosei Yasumoto; Kimitoshi Kohno
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

4.  P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.

Authors:  S Al-Bahlani; M Fraser; A Y C Wong; B S Sayan; R Bergeron; G Melino; B K Tsang
Journal:  Oncogene       Date:  2011-04-25       Impact factor: 9.867

5.  Some facts and thoughts: p73 as a tumor suppressor gene in the network of tumor suppressors.

Authors:  Lakshmanane Boominathan
Journal:  Mol Cancer       Date:  2007-04-03       Impact factor: 27.401

6.  The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.

Authors:  Boh-Ram Kim; Kyungsil Yoon; Hyun-Jung Byun; Seung Hee Seo; Seung-Hoon Lee; Seung Bae Rho
Journal:  Oncotarget       Date:  2014-08-15

7.  Hsp72 mediates TAp73α anti-apoptotic effects in small cell lung carcinoma cells.

Authors:  Ulrika Nyman; Naveen Reddy Muppani; Boris Zhivotovsky; Bertrand Joseph
Journal:  J Cell Mol Med       Date:  2011-08       Impact factor: 5.310

8.  Discrimination of carcinogens by hepatic transcript profiling in rats following 28-day administration.

Authors:  Hiroshi Matsumoto; Yoshikuni Yakabe; Koichi Saito; Kayo Sumida; Masaru Sekijima; Koji Nakayama; Hideki Miyaura; Fumiyo Saito; Masanori Otsuka; Tomoyuki Shirai
Journal:  Cancer Inform       Date:  2009-11-13

9.  TAp73β-mediated suppression of cell migration requires p57Kip2 control of actin cytoskeleton dynamics.

Authors:  Johanna Rodhe; Edel Kavanagh; Bertrand Joseph
Journal:  Oncotarget       Date:  2013-02

10.  Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.

Authors:  Ying-Cheng Chiang; Han-Wei Lin; Chi-Fang Chang; Ming-Cheng Chang; Chi-Feng Fu; Tsung-Ching Chen; Shu-Feng Hsieh; Chi-An Chen; Wen-Fang Cheng
Journal:  Oncotarget       Date:  2015-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.